Global Randomization and Inventory Awareness: 2 Case Studies on Mid-Study RTSM Transitions and Modifications

Randomization and Trial Supply Management (RTSM) systems (IRT, IWRS, IxRS) provide real-time global awareness of enrollment and inventory data. RTSM systems eliminate the blind spots of paper source and excels and provide dynamic features that can be enabled and modified throughout the study lifecycle. Just as important is the team behind the technology; the team must be agile to keep up with the dynamic nature of clinical studies.

Axiom’s Unified eClinical Platform – Fusion offers RTSM modules for complete randomization and inventory management via a single log-on. With optional built in EDC, Fusion’s RTSM modules interact with all too-often siloed data, to provide a truly centralized platform.

In this webinar, we will be looking at how Axiom helped two leading pharmaceutical companies implement, support, and monitor RTSM-related activities through mid-study changes, one a transition from both paper and IRT and the second, an initial implementation with modifications based on data trends. Register to know more on how to improve global RTSM awareness and best practices for mid-study changes.

Speakers

Andrew Schachter, Founder & CEO, Axiom Real-Time Metrics

Andrew Schachter is the Founder and Chief Executive Officer of Axiom Real-Time Metrics, Inc.,where he provides the visionary leadership integral to the company’s more than 19 years of eClinical technology and managed services success. Axiom’s Fusion eClinical Suite, premier unified eClinical platform, has been used to run hundreds of studies across a wide range of therapeutic areas, from Phase I to global Phase III studies and registries.

Message Presenter

Heather DiFruscia, Associate Director IWRS/ RTSM, Axiom Real-Time Metrics

Heather DiFruscia is the Associate Director RTSM / IWRS and is responsible for managing and overseeing the RTSM department operations, strategy, processes, and software product development.

Message Presenter

Lauren Glenn, Director, Clinical Operations at SwanBio Therapeutics

Lauren Glenn is the Director, Clinical Operations at SwanBio Therapeutics. She has spent the last 15 years at small biotech companies where she was responsible for leading the Clinical Operations group, development of technology and process solution and operational execution of clinical trials.

Message Presenter